Skip to main content
Erschienen in: Breast Cancer Research and Treatment 3/2008

01.06.2008 | Clinical Trial

Sentinel node biopsy in patients with multiple breast cancer

verfasst von: Hee Jeong Kim, Jung Sun Lee, Eun Hwa Park, Sung Lim Choi, Woo Sung Lim, Mi Ae Chang, Bo Kyong Ku, Gyong Yup Gong, Byung Ho Son, Sei Hyun Ahn

Erschienen in: Breast Cancer Research and Treatment | Ausgabe 3/2008

Einloggen, um Zugang zu erhalten

Abstract

Background: Multicentric or multifocal breast cancer is considered a limitation for sentinel lymph node biopsy (SLNB). Studies showing that all quadrants of the breast drain via common afferent lymphatic channels indicate that multiple tumors do not affect lymphatic drainage. We therefore assessed the accuracy of SLNB in patients with multiple breast tumors. Methods: Of the 942 breast cancer patients who underwent SLNB using radioisotope at Asan Medical Center between January 2003 and December 2006, 803 had unifocal and 139 had multiple tumors. Axillary dissection after SLNB was performed on 884 patients, 757 with unifocal and 127 with multiple tumors. All patients underwent lymphatic scintigram for removal of sentinel lymph nodes (SLNs). The clinical characteristics and accuracy of SLNB was compared in patients with unifocal and multiple breast cancer. Results: In the multiple tumor group, 2.68 ± 0.84 SLNs were identified in 136 of 139 patients (identification rate, 97.84%); 81.5% of SLNs were identified by scintigram. The incidence of axillary metastases was 29.50% (41/139). SLNB accuracy was 97.63% (124/127), with a false negative (FN) rate of 7.89% (3/38). In the unifocal group, 2.67 ± 0.96 SLNs were identified in 787 of 803 patients (identification rate, 98.00%); 84.8% of SLNs were identified by scintigram. The incidence of axillary metastasis was 22.04% (177/803). SLNB accuracy was 98.02% (742/757), with a FN rate of 8.62% (15/174). The accuracy and FN rate of SLNB did not differ significantly between unifocal and multiple breast cancer. Conclusion: The accuracy of SLNB in multiple breast cancer is comparable to its accuracy in unifocal cancer. These findings indicate that SLNB can be used an as alternative to complete axillary lymph node dissection in patients with multiple breast tumors.
Literatur
1.
Zurück zum Zitat Schwartz GF, Guiliano AE, Veronesi U (2002) Proceeding of the consensus conference of the role of sentinel lymph node biopsy in carcinoma or the breast. In: The breast 8(3):124–138 Schwartz GF, Guiliano AE, Veronesi U (2002) Proceeding of the consensus conference of the role of sentinel lymph node biopsy in carcinoma or the breast. In: The breast 8(3):124–138
2.
Zurück zum Zitat D’Eredita G, Giardina C, Ingravallo G et al (2007) Sentinel lymph node biopsy in multiple breast cancer using subareolar injection of the tracer. The breast 16(3):316–322PubMedCrossRef D’Eredita G, Giardina C, Ingravallo G et al (2007) Sentinel lymph node biopsy in multiple breast cancer using subareolar injection of the tracer. The breast 16(3):316–322PubMedCrossRef
3.
Zurück zum Zitat Layeeque R, Tilman RH, Korourian S et al (2003) Subareolar sentinel node biopsy for multiple breast cancers. Am J Surg 186:730–736PubMedCrossRef Layeeque R, Tilman RH, Korourian S et al (2003) Subareolar sentinel node biopsy for multiple breast cancers. Am J Surg 186:730–736PubMedCrossRef
4.
Zurück zum Zitat Goyal A, Newcombe RG, Mansel RE et al (2004) Sentinel lymph node biopsy in patients with multifocal breast cancer. EJSO 30:475–479PubMedCrossRef Goyal A, Newcombe RG, Mansel RE et al (2004) Sentinel lymph node biopsy in patients with multifocal breast cancer. EJSO 30:475–479PubMedCrossRef
5.
Zurück zum Zitat Klimberg VS, Rubio IT, Henry R et al (1999) Subareolar versus peritumoral injection for location of sentinel lymph node. Ann Surg 229:860–864PubMedCrossRef Klimberg VS, Rubio IT, Henry R et al (1999) Subareolar versus peritumoral injection for location of sentinel lymph node. Ann Surg 229:860–864PubMedCrossRef
6.
Zurück zum Zitat Tuttle TM, Colbert M, Christensen R et al (2002) Subareolar injection of 99 m-Tc facilitates sentinel lymph node identification. Ann Surg Oncol 9:77–81PubMedCrossRef Tuttle TM, Colbert M, Christensen R et al (2002) Subareolar injection of 99 m-Tc facilitates sentinel lymph node identification. Ann Surg Oncol 9:77–81PubMedCrossRef
7.
Zurück zum Zitat Borgstein PJ, Meijer S, Pijpers R (1997) Intradermal blue dye to identify sentinel lymph node in breast cancer. Lancet 349:1668–1669PubMedCrossRef Borgstein PJ, Meijer S, Pijpers R (1997) Intradermal blue dye to identify sentinel lymph node in breast cancer. Lancet 349:1668–1669PubMedCrossRef
8.
Zurück zum Zitat Chao C, Wong SL, Woo C et al (2001) Reliable lymphatic drainage to axillary sentinel lymph nodes regardless of tumor location within the breast. Am J Surg 182:307–311PubMedCrossRef Chao C, Wong SL, Woo C et al (2001) Reliable lymphatic drainage to axillary sentinel lymph nodes regardless of tumor location within the breast. Am J Surg 182:307–311PubMedCrossRef
9.
Zurück zum Zitat Kern KA (2001) lymphoscintigraphic anatomy of sentinel lymphatic channels after subareolar injection of technetium 99 m sulfur colloid. J Am Coll Surg 193:601–608PubMedCrossRef Kern KA (2001) lymphoscintigraphic anatomy of sentinel lymphatic channels after subareolar injection of technetium 99 m sulfur colloid. J Am Coll Surg 193:601–608PubMedCrossRef
10.
Zurück zum Zitat Mertz L, Mathelin C, Marin C et al (1999) Subareolar injection of 99m-Tc sulfur colloid for sentinel node identification in multifocal invasive breast cancer. Bull Cancer 86:939–945PubMed Mertz L, Mathelin C, Marin C et al (1999) Subareolar injection of 99m-Tc sulfur colloid for sentinel node identification in multifocal invasive breast cancer. Bull Cancer 86:939–945PubMed
11.
Zurück zum Zitat Schrenk P, Wayand W (2001) Sentinel-node biopsy in axillary lymph node staging for patients with multicentric breast cancer. Lancet 357:122PubMedCrossRef Schrenk P, Wayand W (2001) Sentinel-node biopsy in axillary lymph node staging for patients with multicentric breast cancer. Lancet 357:122PubMedCrossRef
12.
Zurück zum Zitat Kumar R, Jana S, Heiba SI et al (2003) Retrospective analysis of sentinel node localization in multifocal, multicentric, palpable or nonpalpable breast cancer. J Nucl Med 44:7–10PubMed Kumar R, Jana S, Heiba SI et al (2003) Retrospective analysis of sentinel node localization in multifocal, multicentric, palpable or nonpalpable breast cancer. J Nucl Med 44:7–10PubMed
13.
Zurück zum Zitat Kumar R, Scott P, Abass A (2004) Sentinel lymph node biopsy in multifocal and multicentric breast cancer. J Am Coll Surg 198:674–676PubMedCrossRef Kumar R, Scott P, Abass A (2004) Sentinel lymph node biopsy in multifocal and multicentric breast cancer. J Am Coll Surg 198:674–676PubMedCrossRef
14.
Zurück zum Zitat Ferrari A, Dionigi P, Rovera F et al (2006) Multifocality and multicentricity are not contraindications for sentinel lymph node biopsy in breast cancer surgery. World J Surg Oncol 4:79–86PubMedCrossRef Ferrari A, Dionigi P, Rovera F et al (2006) Multifocality and multicentricity are not contraindications for sentinel lymph node biopsy in breast cancer surgery. World J Surg Oncol 4:79–86PubMedCrossRef
15.
Zurück zum Zitat Ozmen V, Muslumanoglu M, Cobioglu N et al (2002) Increased false negative rate in sentinel lymph node biopsies in patients with multifocal breast cancer. Breast Cancer Res Treat 76:237–244PubMedCrossRef Ozmen V, Muslumanoglu M, Cobioglu N et al (2002) Increased false negative rate in sentinel lymph node biopsies in patients with multifocal breast cancer. Breast Cancer Res Treat 76:237–244PubMedCrossRef
16.
Zurück zum Zitat Tousimis E, Van Zee KJ, Fey JV et al (2003) The accuracy of sentinel lymph node biopsy in multicentric and multifocal invasive breast cancer. J Am Coll Surg 197:529–535PubMedCrossRef Tousimis E, Van Zee KJ, Fey JV et al (2003) The accuracy of sentinel lymph node biopsy in multicentric and multifocal invasive breast cancer. J Am Coll Surg 197:529–535PubMedCrossRef
17.
Zurück zum Zitat Gentilini O, Tririfo G, Soteldo J et al (2006) Sentinel lymph node biopsy in multicentric breast cancer. The experience of the European Institute of Oncology. Eur J Surg Oncol 32:507–510PubMedCrossRef Gentilini O, Tririfo G, Soteldo J et al (2006) Sentinel lymph node biopsy in multicentric breast cancer. The experience of the European Institute of Oncology. Eur J Surg Oncol 32:507–510PubMedCrossRef
18.
Zurück zum Zitat Kim JH, Heerdts AS, Cody HS, Van Zee KJ (2002) Sentinel lymph node drainage in multicentric breast cancer. Breast J 8:356–361CrossRef Kim JH, Heerdts AS, Cody HS, Van Zee KJ (2002) Sentinel lymph node drainage in multicentric breast cancer. Breast J 8:356–361CrossRef
Metadaten
Titel
Sentinel node biopsy in patients with multiple breast cancer
verfasst von
Hee Jeong Kim
Jung Sun Lee
Eun Hwa Park
Sung Lim Choi
Woo Sung Lim
Mi Ae Chang
Bo Kyong Ku
Gyong Yup Gong
Byung Ho Son
Sei Hyun Ahn
Publikationsdatum
01.06.2008
Verlag
Springer US
Erschienen in
Breast Cancer Research and Treatment / Ausgabe 3/2008
Print ISSN: 0167-6806
Elektronische ISSN: 1573-7217
DOI
https://doi.org/10.1007/s10549-007-9674-9

Weitere Artikel der Ausgabe 3/2008

Breast Cancer Research and Treatment 3/2008 Zur Ausgabe

Umsetzung der POMGAT-Leitlinie läuft

03.05.2024 DCK 2024 Kongressbericht

Seit November 2023 gibt es evidenzbasierte Empfehlungen zum perioperativen Management bei gastrointestinalen Tumoren (POMGAT) auf S3-Niveau. Vieles wird schon entsprechend der Empfehlungen durchgeführt. Wo es im Alltag noch hapert, zeigt eine Umfrage in einem Klinikverbund.

CUP-Syndrom: Künstliche Intelligenz kann Primärtumor finden

30.04.2024 Künstliche Intelligenz Nachrichten

Krebserkrankungen unbekannten Ursprungs (CUP) sind eine diagnostische Herausforderung. KI-Systeme können Pathologen dabei unterstützen, zytologische Bilder zu interpretieren, um den Primärtumor zu lokalisieren.

Sind Frauen die fähigeren Ärzte?

30.04.2024 Gendermedizin Nachrichten

Patienten, die von Ärztinnen behandelt werden, dürfen offenbar auf bessere Therapieergebnisse hoffen als Patienten von Ärzten. Besonders gilt das offenbar für weibliche Kranke, wie eine Studie zeigt.

Adjuvante Immuntherapie verlängert Leben bei RCC

25.04.2024 Nierenkarzinom Nachrichten

Nun gibt es auch Resultate zum Gesamtüberleben: Eine adjuvante Pembrolizumab-Therapie konnte in einer Phase-3-Studie das Leben von Menschen mit Nierenzellkarzinom deutlich verlängern. Die Sterberate war im Vergleich zu Placebo um 38% geringer.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.